Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study

05.06.2023 - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that results from the Phase 3 CARTITUDE-4 ...

Related Keywords

Japan ,China ,United States ,New Jersey ,American ,Mythili Koneru ,Hemophagocytic Lymphohistiocytosis ,Binod Dhakal ,Exchange Commission On ,Janssen Biotech Inc ,Japan Ministry Of Health ,European Hematology Association ,American Society Of Clinical Oncology ,Drug Administration ,American Society Of Oncology Annual Meeting ,European Commission For The Treatment Of Patients ,Twitter ,American Cancer Society ,College Of Wisconsin ,Legend Biotech Corporation Stock ,Nasdaq ,Division Of Hematology ,European Commission ,Linkedin ,Medicinal Devices Agency ,Community Register Of Orphan Medicinal Products ,Associate Professor ,Medical College ,Chief Medical Officer ,Demonstrated Deep ,Year Follow Up Data ,Legend Biotech ,Janssen Biotech ,Release Syndrome ,Effector Cell Associated Neurotoxicity Syndrome ,Macrophage Activation Syndrome ,Risk Evaluation ,Mitigation Strategy ,Nerve Palsies ,Recurrent Cytopenias ,Igg Hypersensitivity Reactions ,Use Machines ,Prescribing Information ,Boxed Warning ,Breakthrough Therapy Designation ,Drug Designation ,European Medicines Agency ,Orphan Medicinal Products ,Private Securities Litigation Reform Act ,Annual Report ,Exchange Commission ,Oncology Annual Meeting ,Long Term Remission ,Refractory Multiple Myeloma After Treatment ,Year Follow Up ,Adult Patients ,Refractory Multiple ,Accessed October ,Granted Conditional Approval ,Receives Approval ,Community Register ,Orphan Medicinal ,Statistics About Multiple Myeloma ,Accessed January ,